A triple GLP-1/GIP/glucagon receptor agonist that produced 24% average weight loss in Phase 2 trials — the highest figure ever recorded for any weight loss compound under study.
Telehealth = physician-prescribed. Research = for research use only, no prescription required. Learn the difference →
Retatrutide (developed by Eli Lilly) is a triple incretin receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. By adding glucagon agonism to the dual GIP/GLP-1 mechanism seen in tirzepatide, retatrutide introduces a third lever for weight loss: glucagon increases energy expenditure in the liver and brown adipose tissue, complementing the appetite suppression from GLP-1 and GIP.
In a Phase 2 trial published in the New England Journal of Medicine (2023), retatrutide at the highest dose (12mg/week) produced a mean 24.2% reduction in body weight over 48 weeks — the largest weight loss ever observed in a clinical drug trial for obesity. Phase 3 trials were initiated in 2024 and results are anticipated in 2026–2027.
Retatrutide is not yet commercially available through telehealth or research channels. It remains in late-stage clinical development. If Phase 3 data mirrors Phase 2 results, regulatory approval could follow by 2027–2028. Patients seeking the most aggressive weight loss currently available should consider tirzepatide through telehealth as the nearest equivalent.
Check back for updates as Phase 3 data emerges. In the meantime, compare available GLP-1 options through our clinic comparison tool.